Cyclacel Pharmaceuticals Exchanges Series C Warrants For 559,395 Common Shares In Agreement With Accredited Investors

Author: Benzinga Newsdesk | September 04, 2025 03:03pm

On September 4, 2025, Cyclacel Pharmaceuticals, Inc. (the "Company") entered into a Warrant Exchange Agreement (the "Exchange Agreement") with certain accredited investors (the "Holders") of existing Series C common stock purchase warrants (the "Exchanged Warrants") to purchase an aggregate of 559,395 shares of the Company's common stock, par value $0.001 per share (the "Common Stock"). The Exchanged Warrants were originally issued pursuant to a securities purchase agreement, dated as of June 20, 2025 by and between the Company and each Holder. Pursuant to the Exchange Agreement, the Company agreed to exchange with the Holders, respectively, the Exchanged Warrants for an aggregate of 559,395 shares of Common Stock (the "New Shares").

Posted In: CYCC